Cytomegalovirus pUL97 Kinase Inhibitor class drugs

1 result
Takeda Pharmaceuticals America, Inc.
Usage: LIVTENCITY is indicated for treating adults and pediatric patients (age 12 and older, weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet treatments.